M&A Science Podcast
 / 
Listen Now:

How Strong Partnerships Lay the Groundwork for Successful Acquisitions

Tomer Stavitsky, SVP Corp Dev at Omnicell [NASDAQ: OMCL]

There's a category of acquisition target that never makes it to the deal table. Interestingly, it’s not because the strategic fit isn't there. It’s because the timing is wrong. Maybe the company is too early, or the PE owner is three years into a five-year hold. Or maybe it’s because your organization doesn't have the bandwidth to integrate right now. 

Most corp dev teams treat that as a dead end, but Tomer Stavitsky sees it as the beginning.

Tomer is SVP and Chief Corporate Development Officer at Omnicell, where he built the corp dev function from the ground up. He came up through Pfizer, J&J, ConvaTec, Intuitive Surgical, and Ginkgo Bioworks, and spent a year and a half running fractional corporate development for startups before joining Omnicell, which gave him a view from the other side of the table.

In this episode, Kison Patel sits down with Tomer to work through what he calls the partner-first approach: a framework for leveraging partnerships as part of the acquisition strategy when a direct deal isn't possible. 

What You'll Learn

  • When partner-first is the right call and when it isn't
  • How to keep the acquisition thesis alive through the partnership execution phase
  • Managing the three-way dynamic between target leadership, the PE owner, and your own org
  • How to negotiate a right of first refusal and what happens when it gets tested
  • Why teams pull the trigger too early, and how to protect the process from internal pressure
  • Applying partner-first to AI-era targets without getting caught in the hype cycle

If you're working through a partner-first deal, the M&A Science membership has frameworks and tools built for exactly this kind of situation. Learn more at mascience.com/membership.

Omnicell is a publicly traded healthcare technology company (NASDAQ: OMCL) focused on pharmacy automation and medication management solutions for health systems and pharmacies. The company serves hospitals, health systems, and retail pharmacy customers with hardware, software, and services designed to improve medication safety and supply chain efficiency.

Industry
Hospitals and Health Care
Founded
1992

Tomer Stavitsky

Tomer Stavitsky is Senior Vice President and Chief Corporate Development Officer at Omnicell (NASDAQ: OMCL), where he leads corporate development and M&A strategy. He brings 15+ years of experience across healthcare, MedTech, digital health, AI, strategy, partnerships, and international M&A, with prior roles at Johnson & Johnson, Pfizer, Intuitive Surgical, ConvaTec, Ginkgo Bioworks, and Allurion. He has appeared on M&A Science to discuss M&A governance, deal teams, steering committees, and leading a deal from diligence through integration.

Recent M&A Science Podcast Episodes

The Back-Office Surprises Nobody Warned You About When Going Global
How to Structure an Acquihire Deal in the AI Talent Race
What Buyers Want from Bankers and Founders
M&A SCIENCE IS SPONSORED BY

M&A Software for optimizing the M&A lifecycle- pipeline to diligence to integration

Explore dealroom

Want to wear your M&A expertise?

Check out the M&A Science store.